乙基3-(3-苯氧基苯基)丙酸酯 | 52888-69-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 乙基3-(3-苯氧基苯基)丙酸酯
• 英文名称: ethyl 3-(3-phenoxyphenyl)propanoate
• 英文别名: 3-Phenoxybenzenepropanoic acid, ethyl ester
• CAS: 52888-69-4
• 化学式: C₁₇H₁₈O₃
• 分子量: 270.328
• InChiKey: QXGXEAXQTZMEEP-UHFFFAOYSA-N

物化性质

• 沸点：
  372.5±25.0 °C(Predicted)
• 密度：
  1.099±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  乙基3-(3-苯氧基苯基)丙酸酯 在 potassium tert-butylate 、 溶剂黄146 、 氯乙酸 作用下， 反应 29.0h， 生成 5-(3-phenoxybenzyl)uracil
  参考文献：
  名称：

  Inhibition of Uridine Phosphorylase. Synthesis and Structure−Activity Relationships of Aryl-Substituted 1-((2-Hydroxyethoxy)methyl)-5-(3-phenoxybenzyl)uracil

  摘要：

  Structure-activity relationship studies on a series of 1-((2-hydroxyethoxy)methyl)-5-(3(substituted-phenoxy)benzyl)uracils as inhibitors of murine liver uridine phosphorylase have led to compounds with IC(50)s as low as 1.4 nM. The two most potent compounds, 10j (3-cyanophenoxy) and 11f (3-chlorophenoxy) were tested in vivo for effects on steady-state concentrations of circulating uridine in mice and rats. Both compounds were substantially more efficacious than BAU (5-benzylacyclouridine) both in vitro and in vivo.

  DOI：

  10.1021/jm960688j
• 作为产物：
  描述：

  间苯氧基苯甲醛 在 platinum(IV) oxide 哌啶 、 吡啶 、 盐酸 、 氢气 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 60.0h， 生成 乙基3-(3-苯氧基苯基)丙酸酯
  参考文献：
  名称：

  Improved Synthesis of 5-Benzyl-2-thiouracils

  摘要：

  Improved methodology for the synthesis of 5-benzyl-2-thiouracils from ethyl phenylpropanoates is reported.

  DOI：

  10.1080/00397919608003878

文献信息

• Design, synthesis and evaluation of novel molecules with a diphenyl ether nucleus as potential antitubercular agents
  作者：Yinghong Yang、Zhenling Wang、Jianzhong Yang、Tao Yang、Weiyi Pi、Wei Ang、Yanni Lin、Yuanyuan Liu、Zicheng Li、Youfu Luo、Yuquan Wei

  DOI：10.1016/j.bmcl.2011.12.022

  日期：2012.1

  A series of compounds with a diphenyl ether nucleus were synthesized by incorporating various amines into the diphenyl ether scaffold with an amide bond. Their antitubercular activities were evaluated against Mycobacterium tuberculosis H37Rv by a microdilution method, with MIC values ranging from 4 to 64 μg/mL. Through structure–activity relationship studies, the two chlorine atoms at 3 and 4 positions

  通过将各种胺掺入具有酰胺键的二苯醚支架中，合成了一系列具有二苯醚核的化合物。通过微稀释法评估了它们的抗结核分枝 杆菌H 37 Rv的抗结核活性，MIC值为4至64μg/ mL。通过结构-活性关系研究，发现R 2基团的苯环的3和4位上的两个氯原子在抗结核活性中起重要作用。最有效的化合物6c通过MTT分析在HepG2细胞系中的MIC值为4μg/ mL，并具有良好的安全性。化合物6c 进一步发现其在卡介苗感染的小鼠模型中有效，为后续优化提供了良好的线索。
• Methods of using .alpha.-phosphonosulfonate squalene synthetase
  申请人：Bristol-Myers Squibb Company

  公开号：US05470845A1

  公开（公告）日：1995-11-28

  .alpha.-Phosphonosulfonate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula ##STR1## wherein R.sup.2 is OR.sup.5 or R.sup.5a ; R.sup.3 and R.sup.5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R.sup.5a is H, alkyl, arylalkyl or aryl; R.sup.4 is H, alkyl, aryl, arylalkyl, or cycloalkyl;, Z is H, halogen, lower alkyl or lower alkenyl; and R.sup.1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts and or prodrug esters of the phosphonic (phosphinic) and/or sulfonic acids.

  提供了抑制酶角鲨烯合酶并从而抑制胆固醇生物合成的.alpha.-磷酸磺酸酯化合物。这些化合物的化学式为##STR1##其中R.sup.2为OR.sup.5或R.sup.5a；R.sup.3和R.sup.5独立地为H、烷基、芳基烷基、芳基或环烷基；R.sup.5a为H、烷基、芳基烷基或芳基；R.sup.4为H、烷基、芳基、芳基烷基或环烷基；Z为H、卤素、低烷基或低烯基；R.sup.1为至少含有7个碳原子的疏水基团，为烷基、烯基、炔基、混合烯基-炔基、芳基、芳基烷基、环烷基、环烷基烷基、杂环芳基、杂环芳基烷基、环杂环烷基、环杂环烷基烷基；如上所述；包括磷酸(亚磷酸)和/或磺酸的药用可接受盐和/或前药酯。
• .alpha.-phosphonosulfinic squalene synthetase inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US05447922A1

  公开（公告）日：1995-09-05

  .alpha.-Phosphonosulfinate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula ##STR1## wherein R.sup.2 is OR.sup.5 or R.sup.5a ; R.sup.3 and R.sup.5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R.sup.5a is alkyl, arylalkyl or aryl; R.sup.4 is H or pharmaceutically acceptable cation;, Z is H, halogen, lower alkyl or lower alkenyl; and R.sup.1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts.

  提供了抑制齐墩果烷合成酶并从而抑制胆固醇生物合成的.alpha.-磷酸亚磺酰基化合物。这些化合物的化学式为##STR1##其中R.sup.2为OR.sup.5或R.sup.5a；R.sup.3和R.sup.5独立地为H、烷基、芳基烷基、芳基或环烷基；R.sup.5a为烷基、芳基烷基或芳基；R.sup.4为H或药用可接受的阳离子；Z为H、卤素、低烷基或低烯基；R.sup.1为至少含有7个碳原子的脂溶性基团，为烷基、烯基、炔基、混合烯基-炔基、芳基、芳基烷基、环烷基、环烷基烷基、杂环芳基、杂环芳基烷基、环杂环烷基、环杂环烷基烷基；如上所述；包括药用可接受的盐。
• Phosphonosulfonates Are Potent, Selective Inhibitors of Dehydrosqualene Synthase and Staphyloxanthin Biosynthesis in <i>Staphylococcus aureus</i>
  作者：Yongcheng Song、Fu-Yang Lin、Fenglin Yin、Mary Hensler、Carlos A. Rodrígues Poveda、Dushyant Mukkamala、Rong Cao、Hong Wang、Craig T. Morita、Dolores González Pacanowska、Victor Nizet、Eric Oldfield

  DOI：10.1021/jm801023u

  日期：2009.2.26

  Staphylococcus aureus produces a golden carotenoid virulence factor called staphyloxanthin (STX), and we report here the inhibition of the enzyme, dehydrosqualene synthase (CrtM), responsible for the first committed step in STX biosynthesis. The most active compounds are halogen-substituted phosphonosulfonates, with K-i values as low as 5 nM against the enzyme and IC50 values for STX inhibition in S. aureus as low as 11 nM. There is, however, only a poor correlation (R-2 = 0.27) between enzyme and cell pIC(50) (= -log(10) IC50) values. The ability to predict cell from enzyme data improves considerably (to R-2 = 0.72) with addition of two more descriptors. We also investigated the activity of these compounds against human squalene synthase (SQS), as a counterscreen, finding several potent STX biosynthesis inhibitors with essentially no squalene synthase activity. These results open up the way to developing potent and selective inhibitors of an important virulence factor in S. aureus, a major human pathogen.
• Inhibition of Staphyloxanthin Virulence Factor Biosynthesis in <i>Staphylococcus aureus</i>: In Vitro, in Vivo, and Crystallographic Results
  作者：Yongcheng Song、Chia-I Liu、Fu-Yang Lin、Joo Hwan No、Mary Hensler、Yi-Liang Liu、Wen-Yih Jeng、Jennifer Low、George Y. Liu、Victor Nizet、Andrew H.-J. Wang、Eric Oldfield

  DOI：10.1021/jm9001764

  日期：2009.7.9

  The gold color of Staphylococcus aureus is derived from the carotenoid staphyloxanthin, a virulence factor for the organism. Here, we report the synthesis and activity of a broad variety of staphyloxanthin biosynthesis inhibitors that inhibit the first committed step in its biosynthesis, condensation of two farnesyl diphosphate (FPP) molecules to dehydrosqualene, catalyzed by the enzyme dehydrosqualene synthase (CrtM). The most active compounds are phosphonoacetamides that have low nanomolar K-i values for CrtM inhibition and are active in whole bacterial cells and in mice, where they inhibit S. aureus disease progression. We also report the X-ray crystallographic structure of the most active compound, N-3-(3-phenoxyphenyl)propylphosphonoacetamide (IC50 = 8 nM, in cells), bound to CrtM. The structure exhibits a complex network of hydrogen bonds between the polar headgroup and the protein, while the 3-phenoxyphenyl side chain is located in a hydrophobic pocket previously reported to bind farnesyl thiodiphosphate (FsPP), as well as biphenyl phosphonosulfonate inhibitors. Given the good enzymatic, whole cell, and in vivo pharmacologic activities, these results should help guide the further development of novel antivirulence factor-based therapies for S. aureus infections.